ProMIS Neurosciences Inc. Common Shares PMN · Stock Open ProMIS Neurosciences Inc. Common Shares in new tab
ProMIS Neurosciences Inc. Common Shares Analysis (PMN)
Is ProMIS Neurosciences Inc. Common Shares a good investment? ProMIS Neurosciences Inc. Common Shares (PMN) is currently trading at 9.38 USD. Market analysts have a consensus price target of 42.63 USD. This suggests a potential upside from current levels.
Earnings Schedule: ProMIS Neurosciences Inc. Common Shares is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -4.55.
Investor FAQ
Does ProMIS Neurosciences Inc. Common Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is ProMIS Neurosciences Inc. Common Shares?
ProMIS Neurosciences Inc. Common Shares is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -10.92.
Company Profile
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
| Split Date | Split Ratio to 1 |
|---|---|
| June 28, 2022 | 1:60 |
| Nov. 28, 2025 | 1:25 |
Community Discussion